AriBio Granted EMA Authorization for Phase 3 Clinical Trial of AR1001

AriBio Granted EMA Authorization for Phase 3 Clinical Trial of AR1001

By, Admin 30 April 2024

AriBio Granted EMA Authorization for Phase 3 Clinical Trial of AR1001 in Alzheimer’s Treatment (POLARIS-AD)

Overview

AriBio Co., Ltd. (AriBio) has received approval from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a phase 3 clinical trial targeting early Alzheimer’s disease. This approval aligns with similar authorizations from the U.S. Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the trial.

Approval for Member States

  • EMA's decision, finalized on April 24th, grants approval for the trial to proceed in several member states including the Czech Republic, Denmark, France, Germany, Italy, Spain, and The Netherlands. 
  • The trial aims to enroll 1,150 participants across 200 sites worldwide.

POLARIS-AD

  • POLARIS-AD is a significant trial evaluating the efficacy and safety of AR1001 (Mirodenafil) in treating early Alzheimer’s disease with confirmed amyloid pathology. 
  • It employs primary and secondary endpoints accepted by FDA and EMA, including the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB) and several others.

AriBio on Efficient Trial

  • AriBio, expressed satisfaction with the trial's expansion into additional European countries, viewing it as a milestone in AR1001's registration program. 
  • He emphasized the company's dedication to efficiently expand the trial into these regions to meet the demand for alternative Alzheimer’s treatments. 
  • The global nature of the trial enhances accessibility to the treatment if its efficacy and safety are demonstrated.

About AR1001

  • AR1001 is a phosphodiesterase-5 (PDE5) inhibitor under investigation as an oral agent for Alzheimer’s disease treatment. 
  • Pre-clinical studies suggest it may offer neuroprotective effects by inhibiting neuron apoptosis and restoring synaptic plasticity, indicating potential disease-modifying effects.

About Trial

  • The trial, AR1001-ADP3-US01 (NCT05531526), is a phase 3 double-blind, randomized, placebo-controlled, multi-center trial evaluating AR1001 in early Alzheimer’s disease patients. 
  • More information about the trial is available on ClinicalTrials.gov.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!